Direct Healthcare Professional Communication "Fluoroquinolones for systemic and inhalation use (LEVOFLOCIN 250, LEVOFLOCIN 500): risk of aortic aneurysm and/or dissection, cardiac valve regurgitation/incompetence"

23.09.2024 958 views

Information letter to healthcare professionals “Fluoroquinolones for systemic and inhalation use (LEVOFLOCIN 250, LEVOFLOCIN 500): risk of aortic aneurysm and/or dissection, cardiac valve regurgitation/insufficiency”PDF · 709 KB

Завантажити

Direct Healthcare Professional Communication "Fluoroquinolones for systemic and inhalation use (LEVOFLOCIN 250, LEVOFLOCIN 500): risk of aortic aneurysm and/or dissection, cardiac valve regurgitation/incompetence"

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Direct Healthcare Professional Communication "Fluoroquinolones for systemic and inhalation use (LEVOFLOCIN 250, LEVOFLOCIN 500): risk of aortic aneurysm and/or dissection, cardiac valve regurgitation/incompetence"

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration